The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's gene therapy for a rare ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Kronos is cutting 83% of its workforce, while Idorsia is considering cutting as many as 270 jobs. Elsewhere, PTC disclosed ...
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of ...
WLAX La Crosse on MSN23h
Aspirus Health is one of area hospitals picking up the slack after HSHS closureWith the closures of HSHS hospitals in Eau Claire and Chippewa Falls closing this past Spring, neighboring hospitals have ...
In northwest Durham, a high school student in crisis led to an officer being injured and taken to a hospital on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback